Table 3.
Clinical features and laboratory data of the reported patients with IgA-IRGN or SAGN.
| IgA-IRGN n = 336 |
SAGN n = 218 |
|||
|---|---|---|---|---|
| Clinical features: | ||||
| AKI or RPGN | 79.1% | 178/225 | 75.0% | 78/104 |
| Nephrotic syndrome | 59.1% | 101/171 | 52.4% | 75/143 |
| Proteinuria | 98.9% | 183/185 | 98.4% | 183/186 |
| Hematuria | 95.0% | 226/238 | 91.4% | 106/116 |
| Purpura | 40.7% | 46/113 | 29.5% | 49/166 |
| Laboratory data: | ||||
| Excretion of urinary protein, g/day | 4.79 (n = 272) | 0–19.06 | 4.68 (n = 125) | 0–16.0 |
| Serum creatinine level, mg/dL | 3.54 (n = 312) | 0.38–21.94 | 3.61 (n = 138) | 0.38–10.4 |
| Serum IgA level, mg/dL | 642.5 (n = 98) | 97–1850 | 685.4 (n = 77) | 97–1850 |
| Elevated serum IgA level | 76.0% | 73/96 | 78.0% | 46/59 |
| Decreased serum C3 level | 33.3% | 74/222 | 34.3% | 60/175 |
| Decreased serum C4 level | 11.0% | 18/163 | 15.5% | 26/168 |
| Positive test for ANCA | 5.1% | 5/99 | 11.4% | 12/105 |
AKI—acute kidney injury; ANCA—antineutrophil cytoplasmic antibody; RPGN—rapidly progressive glomerulonephritis.